NASDAQ$ABUS
Arbutus Biopharma Corp · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported second quarter 2022 financial results and provided corporate updates.
Arbutus Biopharma reported a revenue increase of $11.9 million compared to the same period in 2021, primarily due to revenue recognition from a license agreement with Qilu. The company's net loss attributable to common shares was $14.2 million, an improvement from the $22.7 million loss in the same quarter of the previous year. The company's cash runway is projected into the second quarter of 2024.
- Presented data at EASL ILC highlighting advancements in RNAi therapeutic AB-729, capsid inhibitor AB-836, and PD-L1 inhibitor AB-101.
- Observed virologic control in five cHBV patients after discontinuing treatment with AB-729 and nucleos(t)ide analog (NA)-therapy.
- Plan to initiate a Phase 1 study with AB-836 in healthy volunteers to characterize ALT increases.
- Advancing development efforts with nsp5 main protease (Mpro) and nsp12 viral polymerase programs for SARS-CoV-2 and future coronavirus outbreaks.
Headline financials
Revenue & EPS history
Arbutus · Revenue · Quarterly
$14.2M
Revenue by segment
Arbutus · $689K total across 1 segment · Q2 2020
- Non-cash Royalty Revenue$689K—100.0%
Forward guidance
The Company expects a net cash burn between $90 to $95 million in 2022, not including the $55 million of proceeds received from Qilu, and believes its cash runway will be sufficient to fund operations into the second quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
-1.3%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-0.4%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+22.2%
Q1 2020
Best reaction
-18.6%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -3.2% | — | |
| Q4 2025 | +4.2% | +1.2% | +4.5% | |
| Q3 2025 | -5.8% | -8.1% | -2.7% | |
| Q1 2025 | -0.9% | -1.9% | +10.7% | |
| Q4 2024 | -2.4% | +3.9% | -1.8% | |
| Q3 2024 | -5.8% | -5.8% | -7.1% | |
| Q2 2024 | -0.8% | -4.0% | +2.7% | |
| Q1 2024 | +0.7% | +5.6% | +24.9% | |
| Q4 2023 | -3.1% | -7.3% | -10.4% | |
| Q3 2023 | -0.5% | -5.9% | +10.6% | |
| Q2 2023 | +2.9% | -2.4% | -1.4% | |
| Q1 2023 | +3.6% | +4.0% | +2.8% | |
| Q4 2022 | +1.8% | +4.3% | +7.8% | |
| Q3 2022 | +0.8% | +7.3% | +6.1% | |
| Q2 2022 | +2.8% | +0.0% | -10.2% | |
| Q1 2022 | +1.6% | -20.5% | +8.4% | |
| Q4 2021 | -9.1% | -6.8% | -0.3% | |
| Q3 2021 | -9.6% | -9.1% | +7.8% | |
| Q2 2021 | +9.1% | +13.8% | +23.6% | |
| Q1 2021 | -15.9% | -20.4% | -11.7% | |
| Q4 2020 | -9.3% | -1.1% | -5.8% | |
| Q3 2020 | -8.8% | +5.9% | +31.0% | |
| Q2 2020 | -16.2% | -18.5% | -44.2% | |
| Q1 2020 | +22.2% | +55.6% | +37.0% | |
| Q4 2019 | -2.0% | -8.3% | -70.0% | |
| Q3 2019 | -4.0% | -3.4% | +53.7% | |
| Q2 2019 | +1.2% | +1.2% | -11.0% | |
| Q1 2019 | -5.4% | -10.0% | -36.4% | |
| Q4 2018 | -8.0% | +2.7% | +9.5% | |
| Q3 2018 | +13.7% | -6.7% | -7.4% | |
| Q2 2018 | -18.6% | -19.4% | -23.2% | |
| Q1 2018 | +3.5% | +8.8% | +7.0% | |
| Q4 2017 | -12.5% | -17.5% | -13.3% | |
| Q3 2017 | +20.4% | +4.6% | +2.8% | |
| Q2 2017 | -4.2% | +1.4% | +15.3% | |
| Q1 2017 | -2.4% | -0.9% | +2.1% | |
| Q4 2016 | -6.0% | -4.5% | +0.0% | |
| Q3 2016 | -3.3% | -4.9% | -12.1% | |
| Q2 2016 | -8.6% | -13.6% | -14.5% | |
| Q1 2016 | -3.8% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -2.3% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -5.1% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2013 | -3.1% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +0.6% | — | — | |
| Q2 2012 | -0.3% | — | — | |
| Q1 2012 | -5.1% | — | — | |
| Q4 2011 | +2.9% | — | — | |
| Q4 2010 | +2.9% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | -4.1% | — | — | |
| Q3 2010 | +0.8% | — | — | |
| Q2 2010 | -0.8% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro